A 72-year-old woman with prior myocardial infarction and chronic kidney disease (eGFR 35 mL/min/1.73m²) is on atorvastatin 80 mg daily. Her lipid panel shows: LDL 95 mg/dL, HDL 38 mg/dL, triglycerides 280 mg/dL. She develops persistent muscle pain and weakness 6 weeks after atorvastatin initiation. Creatine kinase (CK) is 1200 U/L (normal <200). What is the most appropriate next step in management?

Explanation

## Clinical Presentation: Statin-Induced Myopathy **Key Point:** This patient has statin-induced muscle injury (myopathy) — elevated CK + myalgia temporally related to statin initiation — a known adverse effect occurring in 1–10% of statin users, more common in elderly patients and those with renal impairment [cite:KD Tripathi 8e Ch 31]. ## Risk Factors Present - **Age 72 years** — elderly patients have higher myopathy risk - **CKD Stage 3b (eGFR 35)** — reduced statin clearance → accumulation - **High-dose atorvastatin (80 mg)** — more myotoxicity than lower doses - **Symptom onset 6 weeks post-initiation** — typical timeline for statin myopathy ## Management Algorithm ```mermaid flowchart TD A["Statin-induced myopathy suspected<br/>(Myalgia + elevated CK)"]:::outcome A --> B["Discontinue statin immediately"]:::action B --> C["Monitor CK weekly until normalization"]:::action C --> D{"CK normalized?"}:::decision D -->|Yes| E["Rechallenge with low-dose statin<br/>or non-statin alternative"]:::action D -->|No| F["Investigate other causes<br/>(myositis, rhabdomyolysis)"]:::action E --> G{"Tolerated?"}:::decision G -->|Yes| H["Continue low-dose statin"]:::outcome G -->|No| I["Use non-statin agents<br/>(ezetimibe, bempedoic acid, PCSK9i)"]:::outcome ``` ## Rationale for Discontinuation **High-Yield:** The standard-of-care approach to statin myopathy is: 1. **Immediate discontinuation** — prevent progression to rhabdomyolysis (CK >5000 U/L with myoglobinuria) 2. **Monitor CK recovery** — typically normalizes within 2–4 weeks 3. **Rechallenge after recovery** — use lower dose, less potent statin, or non-statin **Clinical Pearl:** Pravastatin and rosuvastatin are less dependent on hepatic metabolism (CYP3A4) and may be better tolerated in renal impairment. However, if myopathy recurs, switch to non-statin agents (ezetimibe + bempedoic acid) to maintain LDL reduction without myotoxicity. ## Why NOT Continue or Reduce Atorvastatin? **Warning:** Continuing or simply reducing the statin dose in the face of active myopathy risks progression to rhabdomyolysis, acute kidney injury, and hyperkalemia — especially dangerous in a patient with baseline CKD (eGFR 35). ## Non-Statin Alternatives in Statin-Intolerant Patients | Agent | Mechanism | LDL ↓ | Use in CKD | Notes | |-------|-----------|-------|-----------|-------| | **Ezetimibe** | Cholesterol absorption inhibitor | 15–20% | Safe | No dose adjustment needed | | **Bempedoic acid** | Uric acid ↓ + modest lipid effect | 10–15% | Safe | May improve gout; mild uricosuric | | **PCSK9 inhibitors** | LDL receptor upregulation | 40–60% | Safe | Expensive; for very high-risk patients | | **Inclisiran** | PCSK9 mRNA silencing | 40–50% | Safe | Newer; twice-yearly dosing | **Tip:** In this patient with prior MI and statin intolerance, a combination of ezetimibe + bempedoic acid can reduce LDL by ~25–35%, which is meaningful for secondary prevention, even if not as potent as a statin. ## Why This Patient Needs Non-Statin Therapy She has established CAD (prior MI) and cannot tolerate statins — abandoning lipid-lowering therapy entirely is not acceptable. Combination non-statin therapy is the pragmatic choice.